Type 1 diabetics with obesity in whom insulin therapy alone is insufficient for glycemic control may additionally benefit from oral treatment with an SGLT2 inhibitor. Recent study results show good results of add-on therapy. However, good adherence and monitoring for ketoacidosis risk are indicated.
You May Also Like
- Case reports: rare skin tumors
Personalized treatment strategy for severe recurrent courses
- Hematologic oncology
Healing potential based on innovative research approaches
- International Vitiligo Task Force
Position paper on trends and current treatment options
- New secondary analysis
Ginkgo biloba alleviated mild neurocognitive deficits
- Journal Club
New real-world data on light urticaria
- Tuberculosis and smoking
Tobacco consumption increases the risk of recurrence and mortality
- Rare diseases: hATTR amyloidosis
What treatment options are available today?
- "Antimicrobial stewardship"